IP licensing and business: Jan. 2-Jan. 15
By Melissa Ritti ( January 15, 2026, 22:24 GMT | Insight) -- January ushered in a flurry of dealmaking in the tech space, but the biggest moves of the new year thus far are being made in the fight against cancer.A mystery “peptide-based asset” is at the center of a $50 million deal between Novartis and Zonsen PepLib Biotech, while Amgen has locked down exclusive rights to develop novel therapeutics for a recently discovered cancer target....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.